| Cancer Diagnosis and Treatment | Lifetime | 5 | FR 1 | 99.89 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 6 | FR 1 | 99.92 |
| Prostate Cancer Treatment and Research | Lifetime | 11 | FR 1 | 99.93 |
| Cancer, Lipids, and Metabolism | Lifetime | 26 | FR 2 | 99.83 |
| Testicular diseases and treatments | Lifetime | 9 | FR 1 | 99.77 |
| Bone health and treatments | Lifetime | 45 | FR 3 | 99.70 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 64 | FR 2 | 99.73 |
| PARP inhibition in cancer therapy | Lifetime | 27 | FR 1 | 99.49 |
| Hormonal and reproductive studies | Lifetime | 64 | FR 1 | 99.42 |
| Multiple Myeloma Research and Treatments | Lifetime | 83 | FR 9 | 99.41 |
| Tumors and Oncological Cases | Lifetime | 54 | FR 2 | 99.18 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 288 | FR 27 | 99.30 |
| Cancer Treatment and Pharmacology | Lifetime | 233 | FR 13 | 99.28 |
| Oral and Maxillofacial Pathology | Lifetime | 287 | FR 2 | 98.42 |
| Urologic and reproductive health conditions | Lifetime | 201 | FR 6 | 98.72 |
| Sarcoma Diagnosis and Treatment | Lifetime | 506 | FR 29 | 98.05 |
| Neuroblastoma Research and Treatments | Lifetime | 367 | FR 21 | 98.02 |
| Renal cell carcinoma treatment | Lifetime | 969 | FR 60 | 96.42 |
| Sexual Differentiation and Disorders | Lifetime | 692 | FR 39 | 95.25 |
| Management of metastatic bone disease | Lifetime | 598 | FR 18 | 94.14 |
| Gestational Trophoblastic Disease Studies | Lifetime | 552 | FR 22 | 86.15 |
| Clusterin in disease pathology | Lifetime | 647 | FR 26 | 55.04 |
| Prostate Cancer Treatment and Research | 2021-2025 | 1 | FR 1 | 99.96 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 3 | FR 1 | 99.89 |
| PARP inhibition in cancer therapy | 2021-2025 | 3 | FR 1 | 99.79 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 7 | FR 1 | 99.74 |
| Prostate Cancer Diagnosis and Treatment | 2021-2025 | 10 | FR 1 | 99.77 |
| Hormonal and reproductive studies | 2021-2025 | 32 | FR 1 | 97.76 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 617 | FR 36 | 97.65 |
| Testicular diseases and treatments | 2021-2025 | 33 | FR 1 | 95.96 |
| Cancer Treatment and Pharmacology | 2021-2025 | 247 | FR 22 | 95.15 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 375 | FR 16 | 95.00 |
| Bone health and treatments | 2021-2025 | 237 | FR 8 | 89.45 |
| Cell death mechanisms and regulation | 2021-2025 | 68 | FR 4 | 87.81 |
| DNA Repair Mechanisms | 2021-2025 | 379 | FR 16 | 87.63 |
| Urologic and reproductive health conditions | 2021-2025 | 259 | FR 6 | 87.71 |
| Estrogen and related hormone effects | 2021-2025 | 688 | FR 32 | 75.52 |
